In the pharmaceutical industry, the active ingredients in drugs are usually manufactured as crystalline solids, and a recurring problem is that of polymorphism. It has been suggested that producing the active pharma ingredients as room temperature ionic liquids could be advantageous,
(a) What is polymorphism?
(b) Why is polymorphism problematical to the pharmaceutical industry? Distinguish between an ‘ionic liquid’ and a ‘room temperature ionic liquid’.
(c) Discuss some of the advantages that room temperature ionic liquids might have over crystalline solids in active pharma ingredients,
(d) Hydrochloride salts, RNH3C1, or quaternary ammonium salts, R4NC1, are common among active pharma ingredients. How would these be converted into ionic liquids? Comment on whether inorganic anions such as [A1CI4]_ or [BF4]“ would be suitable in these ionic liquids
We need at least 10 more requests to produce the solution.
0 / 10 have requested this problem solution
The more requests, the faster the answer.